ImmuPharma (LON:IMM), a specialist drug discovery and development company, today announced that, further to the announcement of 13 December 2019, that its shares will be admitted to trading on Euronext
The Life Sciences Division’s Navid Malik discusses ImmuPharma in this exclusive interview with DirectorsTalk.
ImmuPharma (LON:IMM), a specialist drug discovery and development company, has today announced that its shares will be admitted to trading on Euronext Growth Brussels under ticker ‘ALIMM’ following the approval
Life Science Division Executive Director and Head of Research Dr Navid Malik joins DirectorsTalk to discuss ImmuPharma plc (LON: IMM). Navid provides an overview of the Life Science Division and how long its
ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women
ImmuPharma’s Tim McCarthy discusses their licencing & development agreement with Avion, the Lanstead deal and the key investment points for investing in IMM in this exclusive interview with DirectorsTalk.
British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals. Avion
ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of
ImmuPharma (LON:IMM), a specialist drug discovery and development company, has announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13-15 January 2020, at the
ImmuPharma (LON:IMM), a specialist drug discovery and development company, has announced a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™ in North America (United
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
